The U.S. Food and Drug Administration announced a resolution to the nation’s saline shortage, a move easing pressure on hospitals that had been forced to delay elective procedures due to the deficit. The announcement comes as a relief to the healthcare sector that has been grappling with supply chain issues.
In a separate development, Bloomberg News reports that a health commission established under the Trump administration is expected to miss its deadline for a report addressing children’s health issues. The report, designed to tackle a ‘chronic disease epidemic,’ was initially expected by August 12, highlighting challenges within federal health planning.
On the research front, a Swedish study reveals that genetic changes can help assess heart disease risks in Type 2 diabetes patients, crucial for targeting individual treatments. Eli Lilly, in the pharmaceutical market, has adjusted its profit forecast upward due to rising demand for its weight-loss drug, Zepbound, despite investor concerns causing a dip in its stock prices.
(With inputs from agencies.)